Greetings from EP Plus!
If you've made it here, you're only a few steps away from the Provisional Registered Pharmacist (PRP) program!
Here are some details about EP Plus Group’s Provisional Registered Pharmacist (PRP) program.
What is EP Plus Group’s PRP Program
- An opportunity for graduates to gain experience at an innovative non-manufacturing pharmaceutical company for 12 months.
- Facilitated by a Master Preceptor through structured training under the guidance of a mentor.
- Compulsory modules & guidelines set by the Ministry of Health (MOH).
What will you gain?
- Experience an innovative healthcare corporation specialising in European medical brands.
- On-the-job learning through various projects and coaching with experienced leader-managers.
- Immersed in EP Plus Group’s Core Values and Culture.
- Gaining Life and Human Skills to be effective leaders.
- Option for an excellent career opportunity in EP Plus Group.
Rotational program
- Business Development
- Commercial Excellence
- Medical Affairs, Pharmacovigilance, Regulatory Affairs and Quality Assurance
- Sales & Marketing
- Supply Chain & Customer Service
Who are we looking for?
- Graduates with a degree in Pharmacy from an institution registered with Pharmacy Board Malaysia.
- Pioneering & Growth Mindset.
- Social Media & Tech Savvy.
- Possesses good interpersonal, communication and presentation skills.
When will it start?
- EP Plus Group's Provisional Registered Pharmacist (PRP) program will start in February 2025.
- However, we will start reaching out to qualified applicants starting from November 2024.
About the Company
EP Plus Group Sdn Bhd
EP Plus Group is a regional healthcare corporation headquartered in Malaysia, with a strong presence in Singapore, Indonesia, and the Philippines. With over 28 years of experience, we build and grow brands into market leaders through our business units – Pharmaceuticals, Fertility Sciences, Medical Aesthetics, and Medical Nutrition. Committed to innovating for better lives, we bring cutting-edge healthcare solutions to patients across Southeast Asia. For more information, please visit https://epplusgroup.com/.